ARK Genomic Revolution ETF

Frequently Asked Questions About ARKG

What does ARKG invest in?

The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.

What is the expense ratio of ARKG?

ARK Genomic Revolution ETF (ARKG) charges an expense ratio of 0.75%. This is the annual fee deducted from fund assets to cover management and operations.

How big is ARKG?

ARK Genomic Revolution ETF (ARKG) manages $1.56B in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is ARKG actively managed or an index fund?

ARKG is actively managed — the manager selects holdings rather than tracking an index. Active funds typically charge higher expense ratios than index funds (ARKG's is 0.75%) in exchange for the discretion to over- or under-weight positions.

When was ARKG launched?

ARK Genomic Revolution ETF (ARKG) launched in October 2014 and is managed by ARK.

How has ARKG performed?

ARKG's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.